BMS-986308 is a selective, orally active renal outer medullary potassium (ROMK) channel inhibitor. It demonstrates greater selectivity for ROMK over hERG channels and is applicable in heart failure research.

BMS-986308 (0.01-3 mg/kg; oral; single dose) demonstrates efficacy in a rat diuresis model with induced volume overload [1]. Animal Model: Male Sprague-Dawley rats (age: 8-12 weeks, 270-300 g) [1]. Dosage: 0.01 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, and 3 mg/kg. Administration: oral, single dose (10% v/v DMAC, 40% v/v PEG400, 50% v/v of 30% w/v HPβCD in 50 mM citrate buffer, pH 4.0). Result: Significantly increased diuresis.